LivaNova (LIVN) Insider Francesco Bianchi Buys 2,383 Shares

Insider Buying and Selling at LivaNova PLC

On June 15, 2026, Francesco Bianchi bought 2,383 shares of LivaNova PLC (LIVN) on the NasdaqGS. This purchase comes at a time when the stock was trading around $78.50. Bianchi's transaction adds to a growing trend of insider buying within the company, showing a commitment to its future prospects.

Recent Insider Purchases

Bianchi's acquisition aligns with several other insider trades on the same day. Enxing Seng Stacy bought 2,383 shares, while Ahmet Tezel, LivaNova's Chief Innovation Officer, added 2,965 shares. Donald Zurbay also bought 2,383 shares, highlighting a collective confidence among insiders. In contrast, Peter Wilver sold 4,042 shares, and Todd Schermerhorn sold 486 shares, valued at about $38,734. These mixed trades reflect varied strategies among LivaNova's leadership.

Stock Performance and Market Context

LivaNova's shares have been trading near their 52-week high of $85.76, showcasing strong investor interest. With a market capitalization of approximately $4.29 billion, the stock has seen a steady rise, which may be contributing to the recent insider buying. The current price is above its 50-day moving average of $79.86, suggesting bullish sentiment among investors.

Analysts Set New Price Targets

Analysts remain optimistic about LivaNova. On October 7, 2026, Barclays initiated coverage with an 'Overweight' rating and a price target of $105. Piper Sandler reiterated its 'Overweight' rating on September 2 with a target of $90, up from $87. Needham maintained its 'Buy' rating on August 5 with a target of $93, reflecting growing confidence in LivaNova's prospects. The average target price among analysts is $89.1, indicating a positive outlook for the stock.

What LivaNova PLC Does

LivaNova PLC, based in Gloucester, UK, specializes in medical technology, focusing on products and therapies for cardiopulmonary and neuromodulation. The company designs and manufactures devices that aid in cardiac procedures and treat conditions like epilepsy and depression. The recent insider purchases may indicate a strong belief in the company's ongoing growth and innovation in the healthcare market.

What’s Next for LivaNova

Investors will be watching LivaNova closely as it approaches its next earnings date on November 4, 2026. The recent insider buying activity reflects confidence in the company's future, especially as it navigates a competitive healthcare landscape. Keep in mind that this insider trading information reflects positions as of June 15, 2026, and may not represent current holdings.